Rosalind Advisors Inc. boosted its stake in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 22.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 628,050 shares of the biopharmaceutical company's stock after acquiring an additional 114,560 shares during the period. MediWound accounts for 7.1% of Rosalind Advisors Inc.'s investment portfolio, making the stock its 5th largest holding. Rosalind Advisors Inc. owned about 6.76% of MediWound worth $11,343,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also bought and sold shares of the company. Rhumbline Advisers bought a new stake in shares of MediWound during the second quarter worth about $131,000. Bank of New York Mellon Corp purchased a new position in MediWound during the second quarter worth about $342,000. Finally, Janney Montgomery Scott LLC bought a new stake in MediWound in the 1st quarter worth about $427,000. Institutional investors own 46.83% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on MDWD. HC Wainwright reissued a "buy" rating and set a $28.00 target price on shares of MediWound in a research report on Friday, October 11th. StockNews.com upgraded MediWound to a "sell" rating in a research report on Monday, August 5th. Finally, Maxim Group upped their target price on shares of MediWound from $25.00 to $30.00 and gave the stock a "buy" rating in a report on Tuesday, July 16th.
Get Our Latest Research Report on MediWound
MediWound Price Performance
MediWound stock traded up $0.08 during midday trading on Wednesday, reaching $17.91. 53,317 shares of the company traded hands, compared to its average volume of 32,574. The business has a 50 day moving average of $17.42 and a two-hundred day moving average of $17.52. The firm has a market capitalization of $193.25 million, a price-to-earnings ratio of -8.29 and a beta of 0.83. MediWound Ltd. has a 12 month low of $7.45 and a 12 month high of $24.00.
MediWound (NASDAQ:MDWD - Get Free Report) last released its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.26). MediWound had a negative return on equity of 52.49% and a negative net margin of 99.17%. The business had revenue of $5.06 million for the quarter, compared to analysts' expectations of $5.07 million. As a group, equities analysts forecast that MediWound Ltd. will post -2.03 EPS for the current year.
About MediWound
(
Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Recommended Stories
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
